company background image
FDBK

FeedbackAIM:FDBK Stock Report

Market Cap

UK£6.7m

7D

-16.7%

1Y

-39.0%

Updated

25 Sep, 2021

Data

Company Financials +
FDBK fundamental analysis
Snowflake Score
Valuation1/6
Future Growth2/6
Past Performance0/6
Financial Health4/6
Dividends0/6

FDBK Overview

Feedback plc, a medical imaging technology company, provides software and systems to those working in the field of medical imaging.

Price History & Performance

Summary of all time highs, changes and price drops for Feedback
Historical stock prices
Current Share PriceUK£0.0063
52 Week HighUK£0.006
52 Week LowUK£0.016
Beta2.18
1 Month Change1.63%
3 Month Change-34.21%
1 Year Change-39.02%
3 Year Change-65.28%
5 Year Change-61.54%
Change since IPO-97.28%

Recent News & Updates

Shareholder Returns

FDBKGB Healthcare ServicesGB Market
7D-16.7%-1.6%0.6%
1Y-39.0%45.7%23.4%

Return vs Industry: FDBK underperformed the UK Healthcare Services industry which returned 45.7% over the past year.

Return vs Market: FDBK underperformed the UK Market which returned 23.4% over the past year.

Price Volatility

Is FDBK's price volatile compared to industry and market?
FDBK volatility
FDBK Beta2.18
Industry Beta0.94
Market Beta1

Stable Share Price: FDBK is more volatile than 90% of UK stocks over the past 3 months, typically moving +/- 11% a week.

Volatility Over Time: FDBK's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of UK stocks.

About the Company

FoundedEmployeesCEOWebsite
195812Tom Oakleyhttps://fbkmed.com/feedback-plc

Feedback plc, a medical imaging technology company, provides software and systems to those working in the field of medical imaging. Its products include TexRAD, a software tool, which extracts and quantifies texture features in radiological images, assisting research into all tumor types, as well as uncovers biomarkers in medical images; and TexRAD Lung for the analysis of lung cancer for clinical use in the European Union. The company also offers Cadran image platform that provides hospitals and research institutes with a comprehensive picture archiving communication system for medical images, as well as equips users with a platform for image handling from all imaging modalities, such as CT and PET scanners; and Bleepa, which combines secure instant messaging with the ability to see clinical grade medical images, including X-rays, and CT and MRI scans using portable devices, such as smartphones or tablets.

Feedback Fundamentals Summary

How do Feedback's earnings and revenue compare to its market cap?
FDBK fundamental statistics
Market CapUK£6.67m
Earnings (TTM)-UK£1.21m
Revenue (TTM)UK£345.98k

19.5x

P/S Ratio

-5.5x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
FDBK income statement (TTM)
RevenueUK£345.98k
Cost of Revenue-UK£1.13k
Gross ProfitUK£347.12k
ExpensesUK£1.55m
Earnings-UK£1.21m

Last Reported Earnings

Nov 30, 2020

Next Earnings Date

n/a

Earnings per share (EPS)-0.0011
Gross Margin100.33%
Net Profit Margin-348.99%
Debt/Equity Ratio0.0%

How did FDBK perform over the long term?

See historical performance and comparison

Valuation

Is Feedback undervalued compared to its fair value and its price relative to the market?

1.11x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate FDBK's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate FDBK's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: FDBK is unprofitable, so we can't compare its PE Ratio to the European Healthcare Services industry average.

PE vs Market: FDBK is unprofitable, so we can't compare its PE Ratio to the UK market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate FDBK's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: FDBK is good value based on its PB Ratio (1.1x) compared to the GB Healthcare Services industry average (6.7x).


Future Growth

How is Feedback forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?

33.6%

Forecasted annual revenue growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: Insufficient data to determine if FDBK's forecast earnings growth is above the savings rate (0.9%).

Earnings vs Market: Insufficient data to determine if FDBK's earnings are forecast to grow faster than the UK market

High Growth Earnings: Insufficient data to determine if earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: FDBK's revenue (33.6% per year) is forecast to grow faster than the UK market (5.4% per year).

High Growth Revenue: FDBK's revenue (33.6% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if FDBK's Return on Equity is forecast to be high in 3 years time


Past Performance

How has Feedback performed over the past 5 years?

-26.6%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: FDBK is currently unprofitable.

Growing Profit Margin: FDBK is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: FDBK is unprofitable, and losses have increased over the past 5 years at a rate of 26.6% per year.

Accelerating Growth: Unable to compare FDBK's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: FDBK is unprofitable, making it difficult to compare its past year earnings growth to the Healthcare Services industry (24.9%).


Return on Equity

High ROE: FDBK has a negative Return on Equity (-20.12%), as it is currently unprofitable.


Financial Health

How is Feedback's financial position?


Financial Position Analysis

Short Term Liabilities: FDBK's short term assets (£4.4M) exceed its short term liabilities (£395.0K).

Long Term Liabilities: FDBK has no long term liabilities.


Debt to Equity History and Analysis

Debt Level: FDBK is debt free.

Reducing Debt: FDBK has not had any debt for past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: Insufficient data to determine if FDBK has enough cash runway based on its current free cash flow.

Forecast Cash Runway: Insufficient data to determine if FDBK has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.


Dividend

What is Feedback current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate FDBK's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate FDBK's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if FDBK's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if FDBK's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of FDBK's dividend in 3 years as they are not forecast to pay a notable one for the UK market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

1.9yrs

Average board tenure


CEO

Tom Oakley (33 yo)

2.42yrs

Tenure

UK£170,000

Compensation

Dr. Thomas James Oakley, also known as Tom,BM(Hons) BSc (Hons), has been Chief Executive Officer of Feedback plc since April 9, 2019 and Director since October 2019. Dr Oakley has been Chief Executive Offi...


CEO Compensation Analysis

Compensation vs Market: Tom's total compensation ($USD232.39K) is about average for companies of similar size in the UK market ($USD323.29K).

Compensation vs Earnings: Tom's compensation has increased whilst the company is unprofitable.


Board Members

Experienced Board: FDBK's board of directors are not considered experienced ( 1.9 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Feedback plc's employee growth, exchange listings and data sources


Key Information

  • Name: Feedback plc
  • Ticker: FDBK
  • Exchange: AIM
  • Founded: 1958
  • Industry: Health Care Technology
  • Sector: Healthcare
  • Market Cap: UK£6.668m
  • Shares outstanding: 1.07b
  • Website: https://fbkmed.com/feedback-plc

Number of Employees


Location

  • Feedback plc
  • Health Foundry
  • Canterbury House
  • London
  • Greater London
  • SE1 7LL
  • United Kingdom

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/09/25 17:46
End of Day Share Price2021/09/24 00:00
Earnings2020/11/30
Annual Earnings2020/05/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.